Announcements Trials
Browse Landscape

Status

No longer available 3Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 809Observational 21Expanded_access 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × Bortezomib × Clear all
NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

NCT00799539 2015-12-02

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Janssen-Ortho Inc., Canada

No longer available
Plasma cell

Multiple Myeloma

NCT01250808 2010-12-01

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Peking University

Available
Plasma cell

Multiple Myeloma

NCT00063791 2007-02-14

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Millennium Pharmaceuticals, Inc.

No longer available
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡